Vnitr Lek 2011, 57(12):1029-1033

Does rational therapy exist in patients with Crohn's disease and ulcerative colitis?

M. Lukáš1,2
1 Klinické a výzkumné centrum pro střevní záněty ISCARE Lighthouse a 1. lékařská fakulta UK Praha, přednosta prof. MUDr. Milan Lukáš, CSc.
2 Ústav klinické biochemie a laboratorní diagnostiky 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Tomáš Zima, DrSc., MBA

Crohn's disease and ulcerative colitis belong to an autoimmune mediated, civilizing diseases having a rise of incidence. The cause of both disease is still unknown with undoubted importance of diet, a lifestyle and using of antimicrobial drugs in the last fifty years. The rational therapy is based to use the drugs with high anti-inflammatory efficacy. The choice of therapy is driven due to disease course in individual patient. The integral part of patients follow up are activities directing to minimize of drug's side effects.

Keywords: Crohn's disease; ulcerative colitis; aminosalicylates; glucocorticosteroids; immunosuppresants; biologic therapy

Received: October 24, 2011; Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukáš M. Does rational therapy exist in patients with Crohn's disease and ulcerative colitis? Vnitr Lek. 2011;57(12):1029-1033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lukáš M, Bortlík M. Etiologie a patogeneze ulcerózní kolitidy. Stále více otazníků než jasných odpovědí. Gastroent a hepatol 2011; 65: 56-64.
    2. Lukáš M, Ďuricová D, Bortlík M. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. Čes a Slov Gastroent a Hepatol 2008; 62: 285-291.
    3. Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011; 13: 475-485. Go to original source... Go to PubMed...
    4. Manza M, Michetti P, Seibold F et al. Treatment algorithm for moderate to severe ulcerative colitis. Swiss Med Wkly 2011; 141: w13235. doi: 10.4414/smw.2011.13235. Go to original source... Go to PubMed...
    5. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845. Go to original source... Go to PubMed...
    6. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031. Go to original source... Go to PubMed...
    7. Travis SP, Stange EF, Léman M et al. European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008; 2: 24-62. Go to original source... Go to PubMed...
    8. Huang X, Lv B, Jin H et al. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol 2011; 67: 759-766. Go to original source... Go to PubMed...
    9. Oussalah A, Evesque L, Laharie D et al. A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. Am J Gastroenterol 2010; 105: 2617-2625. Go to original source... Go to PubMed...
    10. Carter CT, Leher H, Smith P. Impact of persistence with Infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011; 17: 385-392.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.